Trends in hospital admissions due to antidepressant-related adverse drug events from 2001 to 2011 in the U.S.

Harish S. Parihar 1*, Hongjun Yin 1, Jennifer L. Gooch 1, Shari Allen 1, Samuel John 1 and Jianwei Xuan 2

Abstract

Background: Depression is a prevalent mental health disorder and the fourth leading cause of disability in the world as per the World Health Organization. Use of antidepressants can lead to adverse drug events (ADEs), defined as any injury resulting from medication use. This study aimed to examine changes in hospital admissions due to antidepressant-related ADEs (ArADEs) among different socio-demographic groups and changes in lengths of stay (LOS) and hospital charges in ArADE admissions from 2001 to 2011.

Methods: The Healthcare Cost and Utilization Project database was used. ArADE admissions in different socio-demographic groups were examined including characteristics such as age, gender, rural/urban, and income. LOS and hospital charges for ArADE cases were compared between 2001 and 2011. Chi-square test and t test were used for statistical analyses.

Results: There were 17,375 and 20,588 ArADE related admissions in 2001 and 2011, respectively. There was a 17.6% increase among the group of 18 to 64 years old and a 64.8% increase among the group of 65 years or older while the other age groups experienced decreased admission rates. Males and females had similar increases. Patients from the lower income areas experienced a two-fold increase while those from the higher income areas experienced a decrease. The mean LOS for all ArADE related admissions increased from 2.18 to 2.81 days and mean hospital charges increased from $8,456.2 to $21,572.5.

Conclusions: There was an increase in ArADE hospital admissions. The greater increase in ArADE admissions among elderly, urban or low-income patients should be noted and addressed by practitioners and policy makers. The large increase in hospital charges needs further research.

Keywords: Adverse drug events, Antidepressants, Hospital admissions, Healthcare Cost and Utilization Project database, Medication errors

Background
Depression is a prevalent mental health disorder and the fourth leading cause of disability in the world as per the World Health Organization (WHO) [1]. Antidepressants are the most common treatment options for depression. In addition, antidepressants are also prescribed for other conditions such as dysthymia, bipolar depression, schizoaffective disorder, post-psychotic depression, generalized anxiety disorder, panic disorder, social phobia, substance abuse disorders, anorexia, bulimia, obsessive compulsive disorder, post-traumatic stress disorder, and chronic pain syndromes [2]. The prevalence of antidepressant use has trended upwards in the United States in the last decade. In 2000 about 6.5% of the adult population in the US was treated with antidepressants while 10.4% were prescribed the medications in 2010 [3]. Long-term users of antidepressants increased from 3.0% to 6.9% over the same time period.

The Institute of Medicine defines adverse drug events (ADEs) as any injury resulting from medication use [4]. The American Society of Health-System Pharmacists (ASHP) defines a significant ADR as any unexpected,
unintended, undesired, or excessive response to a drug that requires discontinuation of the drug, changing the drug therapy, modifying the dose, necessitates admission to a hospital; prolongs stay in a health care facility, necessitates supportive treatment, significantly complicates diagnosis, negatively affects prognosis or results in temporary or permanent harm, disability, or death [5]. Severe adverse drug effects caused by antidepressants may lead to mortality, including self-inflicted injuries, myocardial infarction, stroke/transient ischemic attack, falls, fractures, upper gastrointestinal bleeding, epilepsy/seizures, and others [6]. In 2011, 89,000 emergency room visits in the U.S were due to adverse drug events (ADEs) related to psychiatric medications including antidepressants [7]. Although, not all ADEs are preventable, there is data to support that approximately one-quarter of all harmful ADEs are preventable [8]. Bates and colleagues found that antidepressants are one of three classes of medications that are significantly associated with preventable ADEs among hospitalized patients [9].

The prevalence and incidence of ADEs may be related to socio-demographic factors. Previous studies showed that among the causes of emergency department visits or hospitalizations, patients aged 65 years or older were associated with higher rate of ADEs than younger patients [10]. A review by Tache et al on prevalence of ADEs among ambulatory care patients showed that elderly patients had higher prevalence rate than younger adult patients, who had higher prevalence rate than pediatrics patients [11]. Studies on the relationship between other socio-demographic factors and ADEs are scarce in the literature. This study aimed to examine changes in incidence of hospital admissions due to antidepressant-related ADEs (ArADEs) from 2001 to 2011 in the U.S., whether the changes are similar across different age groups, if other socio-demographic factors (sex, income, and urban/rural setting) influence any of the observed changes in different age groups; and to examine changes in lengths of stay (LOS) and hospital charges in ArADE hospitalizations from 2001 to 2011.

Methods
A retrospective secondary data analysis was conducted using Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS) database. This study was approved by The Institutional Review Board of the Philadelphia College of Osteopathic Medicine.

The HCUP is a family of databases sponsored by the Agency for Health Research and Quality and covers community hospitals from more than 40 states [12]. HCUP databases are derived from hospital administrative data, which include diagnoses and procedures, discharge status, patient demographics, and charges as well as characteristics of the hospitals such as teaching status, urban or rural location and size. We used the National Inpatient Sample (NIS) data from the HCUP database. The NIS data included inpatient care from all-payer hospitals. After applying weights, the NIS data estimate about 36 million hospitalizations nationally [13].

In the HCUP data, age was recorded in years and race was categorized into six groups: white, black, Hispanic, Asian and Pacific Islander, Native American, and other. Location of a hospital was recorded as either rural or urban. Median income of zip code of patient’s residence was categorized into four quartiles.

Identification of ArADE admissions
ADEs are defined as any injury resulting from medication use. For this study, Illicit drug use and cases of intentional harm or self-inflicted injury were excluded (ICD codes E950.0-E950.9, Suicide and self-inflicted poisoning; E962.0-E962.9, Assault by poisoning; E980.0-E980.9 Poisoning undetermined whether accidentally or purposely inflicted). The HCUP database recorded up to 15 diagnoses in 2001 and up to 25 diagnoses in 2011 for general ADE-associated diagnosis of each inpatient stay record. The diagnoses were recorded in International Statistical Classification of Diseases and Related Health Problems, 9th revision (ICD-9) codes. The ICD-9 codes used to identify ArADEs were retrieved from a report by Lucado et al. [14]. Primary diagnoses of ArADE were considered as an indicator of ArADE admissions.

Statistical analysis
Weights of individual inpatient stays provided in the database were used to estimate the national total. ArADEs in different socio-demographic groups were examined including age, race, gender, rural/urban, and median income in a patient’s residential area. Age was categorized into 0 to 6, 7 to 17, 18 to 64, and 65 years or older. LOS and hospital charges for ArADE cases were compared between 2001 and 2011. Chi-square test was used to compare changes in ADEs relative to the change in total number of hospital admissions. Student’s T-test was used to compare changes in LOS and hospital charges. Given the highly skewed distribution of LOS and hospital charges, the two variables were transformed by taking square root before T-tests were conducted. A p-value of ≤0.01 was considered statistically significant. To more accurately reflect the changes in each subgroup relative to the change in total ArADE admissions over time, percentage changes in rates (rate was calculated as ArADE admission in a subgroup divided by total ArADE admissions in the corresponding year) for each subgroup were also calculated (Table 1). To simplify the presentation for changes by age and income, patients from areas with income in the lower two quartiles were lumped together (“bottom-half”) and patients from areas with
Changes in ArADE admissions by age

| Age (years) | 2001 | 2011 | Percentage change in admissions rate \(\%\) |
|------------|------|------|------------------------------------------|
| ≤ 6        | 272  | 233  | 25.72                                    |
| 7–17       | 1,863.4 | 1,586 | 26.20                                    |
| 18–64      | 14,280 | 16,787 | 1.94                                     |
| ≥ 65       | 656.37 | 1,082 | 42.94                                    |

Percentage changes in rate. Rate was calculated by dividing ArADE admissions or admissions in each age group by total number of all admissions of the respective year. Percentage change was calculated using 2001 rate as the base.

Results

Changes in number of ArADE admissions from 2001 to 2011 between different demographic groups are presented in Tables 1, 2, 3 and 4. Due to a large number of records in 2001 that were missing race data, results on changes of ArADE admissions by race are not presented. The four age groups experienced different changes in ArADE admissions changed by 122.5% and 38.9% in the areas of bottom-half income and areas of top-half income respectively. For the group of 18 to 64 years old, ArADE admissions increased 14.3% and 14.9% respectively. Conversely, the admission in the group of 18 to 64 years and ≥65 years showed an increase of 17.6% and 64.8% respectively. Rates for ≤6 years and 7–17 years old patients decreased by 25.72% and 26.20% respectively. Conversely, rates for the groups of 18–64 years and ≥65 years showed an increase of 1.94% and 42.94% respectively.

There was no significant difference between males and females in terms of change over time in overall ArADE admissions (\(p > 0.01\), Table 2). When specific age groups were examined, there was a significantly larger increase in rate of ArADE admissions among males than their female counterparts for the group of 18 to 64 years old (\(p < 0.01\)). Specifically, ArADE admissions in females increased by 14.8% and 22.9% respectively. Changes in rates in female and male patients were 1.3% and 3.1% respectively. There was no significant difference found between males and females for the other three groups (≤6, 7–17, and ≥65 years old) in terms of change (\(p > 0.01\)).

As shown in Table 3, there was a significant larger increase in ArADE admissions among patients from areas of bottom-half income than their top-half counterparts (\(p < 0.01\)). Specifically, ArADE admissions in bottom-half areas increased by 113.7% while ArADE admissions in top-half areas decreased by 25.2% respectively.

Changes in number of ArADE Admissions from 2001 to 2011 by age and sex

| Age (years) | 2001 | 2011 | Percentage change in admissions rate \(\%\) |
|------------|------|------|------------------------------------------|
| Females    | 11,342 | 5,730 | 12,854 | 6,834 | 13.3\(^{pb}\) | 19.3\(^{pb}\) |
| Males      | 5,730 | 128 | 6,834 | 313 | 48.5 | 31.9 |

Percentage changes in rate. Rate was calculated by dividing ArADE admissions or Admissions in each age group by total number of all admissions of the respective year. Percentage change was calculated using 2001 rate as the base.

Rate change in number of ArADE admissions from 2001 to 2011 using 2001 as the base.

\(^{pb}\) \(p \leq 0.01\), which indicates change in rates over time were significantly different between males and females in the specific age group.
income respectively. However, the changes in rates in the corresponding income groups were much greater for the ≤6 and ≥65 years old groups than the 7 to 17 and 18 to 64 years old groups. Specifically, for the ≤6 years old group, changes in rates in bottom-half and top-half areas were -49.8% and -5.7% respectively. For the ≥65 years old group, changes in rates in the bottom-half and top-half areas were 4.2% and 85.7% respectively.

The changes in ArADE admissions from 2001 to 2011 by age and urban/rural setting of a hospital are presented in Table 4. There was a 22.8% increase in ArADE admissions among urban hospitals and a 14.6% decrease among rural hospitals. This change was statistically significant ($p<0.01$). Changes over time were significantly different between the urban and rural hospitals for all age groups as presented in Table 4 ($p<0.01$). The changes in rates among urban and rural hospitals showed similar direction (increase or decrease) for each age group.

As shown in Table 5, the mean LOS of ArADE admissions were 2.18 days in 2001. Change in mean LOS of ArADE admissions from 2001 to 2011 was 0.63 days, which was statistically significant ($p<0.01$). Changes in mean LOS of ArADE admissions for the 7–17 years old and 18–64 years old groups were statistically significant, which was 0.42 and 0.64 days respectively.

Mean hospital charges more than doubled from $8,456.2 to $21,572.5 ($p<0.01$, Table 6) for ArADE admissions when all age groups were considered. When the different age groups were analyzed separately, changes in mean hospital charges were statistically significant for all four age groups ($p<0.01$).

### Discussion

The present study was the first to examine the change in ArADE hospital admissions over time (between 2001 and 2011) in the U.S. First, there was a significantly higher increase in ArADE admissions as compared to all-cause admissions. According to data published by Agency for Healthcare Research and Quality and IMS Health, the number of prescriptions for antidepressants increased by approximately 98% from 2001 to 2011 [15, 16]. Thus, the percentage increase in ArADE admissions is less than the percentage increase in

| Table 3 | Changes in ArADE Admissions from 2001 to 2011 by age and neighborhood income |
|---------|---------------------------------|
| 2001 (income) | 2011 (income) | Percentage change in admissions ratea |
| Bottom 50% | Top 50% | Bottom 50% | Top 50% | Bottom 50% | Top 50% |
| ArADE admissions* | 4,972 | 12,100 | 10,624 | 9,054 | 113.7b | -25.2b |
| ArADE admissions by age group | | | | | | |
| ≤ 6 | 109 | 163 | 117 | 115 | -49.8 | -5.7 |
| 7–17† | 509 | 1,354 | 820 | 766 | -24.6 | -24.4 |
| 18–64† | 4,150 | 10,131 | 9,233 | 7,545 | 4.1 | -0.5 |
| ≥ 65† | 204 | 452 | 454 | 628 | 4.2 | 85.7 |

| Table 4 | Changes in ArADE Admissions from 2001 to 2011 by age and urban/rural setting of a hospital |
|---------|---------------------------------|
| 2001 | 2011 | Percentage change in admissions ratea |
| Urban | Rural | Urban | Rural | Urban | Rural |
| ArADE admissions* | 13,677 | 3,395 | 16,789 | 2,899 | 22.8b | -14.6b |
| ArADE admissions by age group | | | | | | |
| ≤ 6† | 190 | 82 | 223 | 10 | -4.4 | -85.8 |
| 7–17† | 1,499 | 364 | 1,378 | 208 | -25.1 | -33.1 |
| 18–64† | 11,443 | 2,838 | 14,214 | 2,573 | 1.2 | 6.2 |
| ≥ 65† | 545 | 111 | 974 | 108 | 45.6 | 13.9 |

*p ≤ 0.01, which indicates there is a significant difference between urban and rural areas with regard to change in ArADE admissions

†p ≤ 0.01, which indicates change in rates over time were significantly different between areas of bottom-half income and top-half income in the specific age group
In addition to unequal changes between age groups, the change in ArADE admissions from 2001 to 2011 was also unequal between sexes, areas of different income levels and urban-rural settings. Olsson and Marcus found that male patients diagnosed with depression had a greater increase in prescriptions per person [20], which may partially explain our finding that male patients had a higher increase in ArADE admissions within the 10 years time period. A closer look at the data showed that the higher increase among males than females occurred in patients 18–64 years old.

When all age groups were considered, areas of the highest income quartile experienced a decrease in ArADE admissions while areas of the lowest income quartile experienced almost a five-fold increase (quartile results were not presented in the tables for simplification purpose). Among patients 65 years or older, areas of the highest income quartile experienced the least increase while the lowest income quartile experienced almost a six-fold increase. This is contrary to the findings by Zhang and colleagues [21] who found that socio-economic disadvantage is not associated with a higher risk of adverse drug reactions. The different trends in areas with different income levels observed in the present study may be partially explained by what was found by Lorant and colleagues [22]. In a meta-analysis, Lorant and colleagues reported that individuals with lower socio-economic status (SES) had higher risk of new depression episodes than those with higher SES and the difference in risk of persisting depression between low and high SES individuals was even greater. However, such difference in risk of depression cannot completely explain the different trends over time found in the present study. Other potential factors may include poor quality of care to patients with depression and less access to timely care in lower-income patients, which could lead to greater increase in ArADE admissions.

The greater increase in ArADE admissions among urban patients in comparison to rural patients can be partially explained by the greater increase in urban population. According to the U.S. census bureau [23],
urban population grew by 12.1% while rural population grew only 0.3% from 2000 to 2010. However, the magnitude of increase in ArADE admissions among urban patients is much greater than the population growth.

Overall, both mean LOS and mean hospital charge for ArADE admissions from 2001 to 2011 showed an increase from 2001 to 2011. Combining with the increased number of ArADE admissions, this suggests that ArADE incurred an increased burden to the society. This study also showed that different age groups experienced different magnitudes of increase in LOS and hospital charges over the time period. While LOS of ArADE admissions increased only slightly when all age groups were considered together, the average and median hospital charges more than doubled. This can partially be attributed to medical cost inflation, which rose by 47.1% in the same time period [24]. The additional increase in hospital charges may be due to the change in case mix associated with greater share of elderly patients and patients who did not receive timely care among other factors. As shown in the results, mean LOS for patients 65 or older actually decreased (although insignificant) while mean hospital charge for that group increased significantly.

The present study has several limitations. In this study, it was assumed that diagnosis recorded in the first ICD-9 code of a hospital admission is the primary diagnosis that caused the admission. Instances of illicit drug use and cases of intentional harm or self-inflicted injury were identified based on ICD code and excluded from the study.. However, we acknowledge that ICD codes are optional for billing purposes and notoriously non-sensitive when used for ADE outcomes of interest. Especially in the case of self-assault or attempted suicide, clinicians may be wary to document such information due to legal and social implications or simply due to lack of background information on the patients. Thus, although some cases of intentional self-harm were excluded from the analyses; however there is a possibility of misclassification bias. We were also limited by the information available in the HCUP databases. Several states do not report the race variable. Hence the incidence of ArADE admissions and differences between different racial groups couldn’t be compared. Additionally, individual patients cannot be followed on different admissions to a hospital due to the lack of a common ID for the same patient. As a result, a patients with multiple ArADE admissions to the included hospitals was counted as multiple patients. Also, it would be noteworthy to mention that there has been a great deal of awareness and research regarding ADEs in general since early 2000. Provider awareness to more appropriately diagnose and code these related conditions (for treatment and billing purposes) could therefore account for the perceived ‘higher’ incidence in 2011.

**Conclusion**

ArADE hospital admissions had significant increase from 2001 to 2011 in the United States especially in the elderly, areas of lower-income and urban patients. The increases have incurred a greater economic burden to the society. Further research is needed to investigate the root causes of these increases and the large increase in hospital charges. It would also be beneficial to examine whether similar trends among the different socio-demographic groups exists for hospital admissions related to ADEs of other drug classes. Currently, various CDC and FDA led programs are being executed with the goal of increasing awareness to medication safety and reducing ADEs. Probably, actions to bolster these initiatives and implementation of novel public health actions are needed to address the increase in ArADE admissions.

**Abbreviations**

ADEs: Adverse drug events; ArADEs: Antidepressant-related ADEs; LOS: Lengths of stay; WHO: World Health Organization; ASHP: The American Society of Health-System Pharmacists; HCUP: Healthcare Cost and Utilization Project; NIS: National Inpatient Sample; ICD-9: International Statistical Classification of Diseases, 9th revision

**Acknowledgements**

The authors would like to thank Philadelphia College of Osteopathic Medicine – GA campus School of Pharmacy for providing resources and support.

**Funding**

The project was partially funded by the Division of Research, Philadelphia College of Osteopathic Medicine.

**Availability of data and materials**

The National Inpatient Sample (NIS) data from the Healthcare Cost and Utilization Project (HCUP) database sponsored by the Agency for Health Research and Quality (AHRQ) was utilized for this project. This dataset is available for purchase from AHRQ.

**Authors’ contributions**

HP & HY participated in the conception and design of the study, data analysis, and interpretation and drafted the manuscript. JG, SA, SJ and JX participated in data analysis. All authors contributed to interpretation of findings and preparing, reading, revising, and approving the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

This study was approved by The Institutional Review Board of the Philadelphia College of Osteopathic Medicine.

**Author details**

1School of Pharmacy, Philadelphia College of Osteopathic Medicine School of Pharmacy-Georgia campus, 625 Old Peachtree Rd NW, Suwanee, GA 30024, USA. 2Health Economic Research Institute, Sun Yat-sen University, Guangzhou, China.

Received: 22 July 2015 Accepted: 9 January 2017
Published online: 19 January 2017
References

1. Mishra S, Swain TR, Mohanty M. Adverse Drug Reaction Monitoring of Antidepressants in the Psychiatry Outpatients Department of a Tertiary Care Teaching Hospital. J Clin Diagn Res. 2013;7(6):1131-4.

2. Andrews PW, Thomson Jr JA, Armitage A, Neale MC. Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. Front Psychol. 2012;3:117.

3. Mojtabar R, Olsson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the National Comorbidity Survey Replication. J Clin Psychiatry. 2008;69(7):1064-74.

4. Aspden P, Wolcott JA, Bootman L, et al. Preventing Medication Errors: Quality Chasm Series. Washington: The National Academy Press Web site; 2007. https://www.nap.edu/read/11623/chapter/1#xvi. Accessed 8 May 2015.

5. American Society of Health-System Pharmacists (ASHP) guidelines on adverse drug reaction monitoring and reporting: American Society of Hospital Pharmacy. Am J Health Syst Pharm. 1995;52:417-419.

6. Coupland C, Dhiman P, Morris R, Arthur A, Barton G, Hippsley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population-based cohort study. BMJ. 2011;343:d4451.

7. Hampton LM, Daubresse M, Chang HY, Alexander GC, Budnitz DS. Emergency Department Visits by Adults for Psychiatric Medication Adverse Events. JAMA Psychiatry. 2014;71(9):1006-14.

8. National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP). About Medication Errors: What is a Medication Error? http://www.nccmerp.org/about-medication-errors. Accessed 8 May 2015.

9. Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, Petersen LA, Small SD, Sweeney BI, Yoder Velt M, Leape LL. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med. 1999;159(21):2553-60.

10. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858-65.

11. Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7-8):977-89.

12. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HUCP). http://www.hcup-us.ahrq.gov/research/data/hcup/index.html. Accessed 1 Feb 2014.

13. Agency for Healthcare Research and Quality. Overview of the National Inpatient Sample (NIS). http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed 1 Feb 2014.

14. Lucado J, Paez K, Elixhauser A. Medication-Related Adverse Outcomes in U.S. Hospitals and Emergency Departments, 2008. April, 2011. http://www.hcup-us.ahrq.gov/reports/statbriefs/db/109.jsp. Accessed 20 Jul 2014.

15. Lindsley CW. 2012 Trends and Statistics for Prescription Medications in the United States: CNS Therapeutics Continue to Hold Leading Positions. ACS Chem Neurosci. 2013;4(8):1133–35.

16. IMS Health. Top Therapeutic Classes by U.S. Dispensed Prescriptions. http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20Trends/2011%20Top-Line%20Market%20Data/Top_Therapy_Classes_by_RX.pdf. Accessed 12 Aug 2014.

17. Mojtabar R, Olsson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. J Clin Psychiatry. 2014;75(2):169-77.

18. Olsson M, Marcus SC. National Patterns in Antidepressant Medication Treatment. Arch Gen Psychiatry. 2009;66(8):848--56.

19. Grohol JM. Top 25 Psychiatric Medication Prescriptions for 2011. http://psychcentral.com/lib/top-25-psychiatric-medications-prescriptions-for-2011-00012586. Accessed 12 Aug 2014.

20. U.S. Census Bureau. Age and Sex Composition: 2010. http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. Accessed 13 Aug 2014.

21. Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009;338:a2752.

22. Lorant V, Deliège D, Eaton W, Robert A, Philippon P, Ansseau M. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol. 2003;157(2):98–112.

23. U.S. Census Bureau. Growth in Urban Population Outpaces Rest of Nation, Census Bureau Reports. http://www.census.gov/newsroom/releases/archives/2010_census/cb12-50.html. Accessed 22 Aug 2014.

24. Department of Labor (Bureau of Labor Statistics). onsumer price indexes for major expenditure classes, 1969–2012. http://www.gpo.gov/fdsys/pkg/ERP-2013/pdf/ERP-2013-table60.pdf. Accessed 22 Aug 2014.